Physician profile
Sumant Inamdar
NPI 1346472917
$6,080.36
in general payments reported to CMS, 2019-2025
9 companies · $659 in 2025
The $659 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.64 · 2021: $108 · 2022: $1,533 · 2023: $3,247 · 2024: $457 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,800 · Food and Beverage: $1,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,800.00 |
| Food and Beverage | $1,562.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pentax of America, INC. | $3,067.55 | 2022-2023 | C2 Cryoballoon |
| Creo Medical INC. | $980.07 | 2022-2024 | Speedboat Ultraslim (Sb1l) |
| Boston Scientific Corporation | $959.97 | 2019-2025 | Exalt Model D, Apollo Esg Nxt System, Spyglass |
| Olympus America INC. | $313.97 | 2022-2025 | Visiglide, Hanarostent Lowaxtm Duodenum/Pylorus(Nnn) |
| Conmed Corporation | $235.06 | 2024-2025 | Conmed Biliary |
| Medtronic, INC. | $208.80 | 2023-2024 | Prodigi, Nexpowder |
| Apollo Endosurgery US INC | $142.04 | 2022 | |
| Olympus Corporation of The Americas | $125.00 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $47.90 | 2025 | Onivyde |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumant Inamdar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.